Asparagine synthethase: A new potential biomarker in ovarian cancer

Philip L. Lorenzi, John N Weinstein

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

L-Asparaginase (L-ASP) is an enzyme drug that has been an asset to leukemia treatment regimens for four decades. Variability in its clinical efficacy, however, has prompted the search for biomarkers capable of distinguishing responders from non-responders. In that regard, the NCI-60 cell line panel has served as a biomarker discovery platform and has led to the identification of a correlation between L-ASP efficacy and asparagine synthetase (ASNS) expression in cultured cells. The presence of that correlation in the ovarian subpanel of the NCI-60 has made a case for repositioning L-ASP to ovarian cancer. This review presents an overview of the biomarker development process, summarizes the efforts that have been invested thus far in developing ASNS as a biomarker for ovarian cancer treatment, highlights the role of RNAi and the limitations of the NCI-60 in that process, and addresses important considerations for next steps in the development of ASNS as a predictive biomarker.

Original languageEnglish (US)
Pages (from-to)61-64
Number of pages4
JournalDrug News and Perspectives
Volume22
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Asparagine
Aspartate-Ammonia Ligase
Ovarian Neoplasms
Asparaginase
Biomarkers
RNA Interference
Cultured Cells
Leukemia
Cell Line
Enzymes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Asparagine synthethase : A new potential biomarker in ovarian cancer. / Lorenzi, Philip L.; Weinstein, John N.

In: Drug News and Perspectives, Vol. 22, No. 1, 01.01.2009, p. 61-64.

Research output: Contribution to journalReview article

@article{7c8850dabb754ca48a81cfdb865d48e8,
title = "Asparagine synthethase: A new potential biomarker in ovarian cancer",
abstract = "L-Asparaginase (L-ASP) is an enzyme drug that has been an asset to leukemia treatment regimens for four decades. Variability in its clinical efficacy, however, has prompted the search for biomarkers capable of distinguishing responders from non-responders. In that regard, the NCI-60 cell line panel has served as a biomarker discovery platform and has led to the identification of a correlation between L-ASP efficacy and asparagine synthetase (ASNS) expression in cultured cells. The presence of that correlation in the ovarian subpanel of the NCI-60 has made a case for repositioning L-ASP to ovarian cancer. This review presents an overview of the biomarker development process, summarizes the efforts that have been invested thus far in developing ASNS as a biomarker for ovarian cancer treatment, highlights the role of RNAi and the limitations of the NCI-60 in that process, and addresses important considerations for next steps in the development of ASNS as a predictive biomarker.",
author = "Lorenzi, {Philip L.} and Weinstein, {John N}",
year = "2009",
month = "1",
day = "1",
doi = "10.1358/dnp.2009.22.11303820",
language = "English (US)",
volume = "22",
pages = "61--64",
journal = "Drug News and Perspectives",
issn = "0214-0934",
publisher = "Prous Science",
number = "1",

}

TY - JOUR

T1 - Asparagine synthethase

T2 - A new potential biomarker in ovarian cancer

AU - Lorenzi, Philip L.

AU - Weinstein, John N

PY - 2009/1/1

Y1 - 2009/1/1

N2 - L-Asparaginase (L-ASP) is an enzyme drug that has been an asset to leukemia treatment regimens for four decades. Variability in its clinical efficacy, however, has prompted the search for biomarkers capable of distinguishing responders from non-responders. In that regard, the NCI-60 cell line panel has served as a biomarker discovery platform and has led to the identification of a correlation between L-ASP efficacy and asparagine synthetase (ASNS) expression in cultured cells. The presence of that correlation in the ovarian subpanel of the NCI-60 has made a case for repositioning L-ASP to ovarian cancer. This review presents an overview of the biomarker development process, summarizes the efforts that have been invested thus far in developing ASNS as a biomarker for ovarian cancer treatment, highlights the role of RNAi and the limitations of the NCI-60 in that process, and addresses important considerations for next steps in the development of ASNS as a predictive biomarker.

AB - L-Asparaginase (L-ASP) is an enzyme drug that has been an asset to leukemia treatment regimens for four decades. Variability in its clinical efficacy, however, has prompted the search for biomarkers capable of distinguishing responders from non-responders. In that regard, the NCI-60 cell line panel has served as a biomarker discovery platform and has led to the identification of a correlation between L-ASP efficacy and asparagine synthetase (ASNS) expression in cultured cells. The presence of that correlation in the ovarian subpanel of the NCI-60 has made a case for repositioning L-ASP to ovarian cancer. This review presents an overview of the biomarker development process, summarizes the efforts that have been invested thus far in developing ASNS as a biomarker for ovarian cancer treatment, highlights the role of RNAi and the limitations of the NCI-60 in that process, and addresses important considerations for next steps in the development of ASNS as a predictive biomarker.

UR - http://www.scopus.com/inward/record.url?scp=62649121971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62649121971&partnerID=8YFLogxK

U2 - 10.1358/dnp.2009.22.11303820

DO - 10.1358/dnp.2009.22.11303820

M3 - Review article

C2 - 19209300

AN - SCOPUS:62649121971

VL - 22

SP - 61

EP - 64

JO - Drug News and Perspectives

JF - Drug News and Perspectives

SN - 0214-0934

IS - 1

ER -